
mRNA-lipid nanoparticles (LNPs) have evolved from COVID-19 vaccines to potential cancer treatments. They're studied for cancer vaccines with neoantigens and intratumoral cytokine injections. This review discusses their potential, targeting strategies, manufacturing hurdles, and clinical prospects in oncology. Preclinical and clinical studies position mRNA-LNPs as a promising oncology treatment avenue, despite challenges that need addressing for successful translation.
Like
Save
Share